# GT Biopharma (GTBP) — Earnings

GTBP · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/gtbp/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2025 |
| Period end | Jun 30, 2025 |
| EPS actual | −$13.75 |
| EPS estimate | −$17.00 |
| EPS surprise | +19.12% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Aug 14, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/109657/000149315225011971/form10-q.htm) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2025 | Aug 14, 2025 | −$17.00 | −$13.75 | 19.12% | — | — |
| Q1 2025 | May 15, 2025 | −$8.25 | −$8.25 | 0.00% | — | — |
| Q4 2024 | Feb 21, 2025 | −$38.75 | −$41.75 | -7.74% | — | — |
| Q3 2024 | Nov 14, 2024 | −$67.50 | −$38.25 | 43.33% | — | — |
| Q2 2024 | Aug 14, 2024 | −$67.50 | −$54.25 | 19.63% | — | — |
| Q1 2024 | May 15, 2024 | −$67.50 | −$41.00 | 39.26% | — | — |
| Q3 2023 | Nov 1, 2023 | −$63.75 | −$45.00 | 29.41% | — | — |
| Q2 2023 | Aug 7, 2023 | −$75.00 | −$41.26 | 44.98% | — | — |
| Q1 2023 | May 15, 2023 | −$108.75 | −$7.50 | 93.10% | — | — |
| Q4 2022 | Mar 30, 2023 | −$131.25 | −$135.00 | -2.86% | — | — |
| Q3 2022 | Oct 31, 2022 | −$82.50 | −$165.00 | -100.00% | — | — |
| Q2 2022 | Aug 15, 2022 | −$131.25 | −$75.00 | 42.86% | — | — |
| Q1 2022 | May 16, 2022 | −$232.50 | −$127.50 | 45.16% | — | — |
| Q4 2021 | Mar 28, 2022 | −$147.50 | −$423.75 | -187.29% | — | — |
| Q3 2021 | Nov 10, 2021 | −$117.50 | −$146.86 | -24.99% | — | — |
| Q2 2021 | Aug 23, 2021 | −$207.50 | −$112.50 | 45.78% | — | — |
| Q1 2021 | May 17, 2021 | −$183.75 | −$1,372.50 | -646.94% | — | — |
| Q4 2020 | Apr 16, 2021 | −$86.25 | −$1,241.25 | -1339.13% | — | — |

## Frequently Asked Questions

### When did GT Biopharma (GTBP) last report earnings?

GT Biopharma last reported on Aug 14, 2025, covering fiscal Q2 2025.

### Did GTBP beat earnings estimates?

Yes. GT Biopharma reported EPS of −$13.75 for Q2 2025 against a −$17.00 estimate — a 19.12% beat.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).